Quantitative detection of residual E. coli host cell DNA by real-time PCR

Journal of Microbiology and Biotechnology

Volumn 20, Issue 10, 2010, Pages 1463-1470

  Lee, Dong Hyuck ^a   Bae, Jung Eun ^a   Lee, Jung Hee ^a   Shin, Jeong Sup ^b,c   Kim, In Seop ^a  

^a Hannam University   (South Korea)

^b Green Cross Company   (South Korea)

^c Ajou University   (South Korea)

Author keywords

E. coli host cell DNA; Real time PCR; Slot blot hybridization assay; Total DNA threshold assay

Indexed keywords

BACTERIAL DNA; GENOMIC DNA; RNA 16S;

ARTICLE; BACTERIUM DETECTION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ESCHERICHIA COLI; GENE AMPLIFICATION; HOST CELL; INTERMETHOD COMPARISON; NONHUMAN; NUCLEOTIDE SEQUENCE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SLOT BLOT HYBRIDIZATION; VALIDATION PROCESS;

BIOTECHNOLOGY; DNA PRIMERS; DNA, BACTERIAL; ESCHERICHIA COLI; HUMANS; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS;

EID: 78149481270     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1004.04035     Document Type: Article

References (27)

1. Banexy, F. 1999. Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 10: 411-421.
2. Brosius, J., T. J. Dull, D. D. Sleeter, and H. F. Noller. 1981. Gene organization and primary structure of a ribosomal RNA operon from Escherichia coli. J. Bacteriol. 62: 293-300.
3. CPMP. 1997. Position Statement on DNA and host cell proteins (HCP) impurities - routine testing versus validation studies. Biotechnology Working Party, Committee for Proprietary Medicinal Product, The European Agency for the Evaluation of Medicinal Product, Human Medicines Evaluation Unit, EU.
4. CPMP. 2001. Position statement on the use of tumourigenic cells of human origin for the production of biological and biotechnological medicinal products. Biotechnology Working Party, Committee for Proprietary Medicinal Product, The European Agency for the Evaluation of Medicinal Products: Evaluation of Medicinal Products for Human Use, EU.
5. FDA. 1997. Points to consider in the manufacture and testing of monoclonal antibody products for human use. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, U.S.A.
6. FDA. 2001. Guidance for industry, bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Center for Veterinary Medicine, U.S.A.
7. ICH. 1996. Q2B Validation of analytical procedures: Methodology (guidance for industry). International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Geneva, Switzerland.
8. Jana, S. and J. K. Deb. 2005. Strategies for efficient production of heterologous proteins in Escherichia coli. Appl. Microbiol. Biotechnol. 67: 289-298.
9. Jeong, H. S., J. H. Shin, Y. N. Park, J. Y. Choi, Y. L. Kim, B. G. Kim, et al. 2003. Development of real-time RT-PCR for evaluation of JEV clearance during purification of HPV type 16 L1 virus-like particles. Biologicals 31: 223-229.
10. Kubista, M., J. M. Andrade, M. Bengtsson, A. Forootan, J. Jonák, K. Lind, et al. 2006. The real-time polymerase chain reaction. Mol. Aspects Med. 27: 95-125.
11. Kung, V. T., P. R. Panfili, E. L. Sheldon, R. S. King, P. A. Nagainis, J. B. Gomez, D. A. Ross, J. Briggs, and R. F. Zuk. 1990. Picogram quantitation of total DNA using DNA-binding proteins in a silicon sensor-based system. Anal. Biochem. 187: 220-227.
12. Lahijani, M., M. Duhon, E. Lusby, H. Betita, and M. Marquet. 1988. Quantitation of host cell DNA contaminate in pharmaceutical-grade plasmid DNA using competitive PCR and enzyme linked immunosorbent assay. Hum. Gene Ther. 9: 1173-1180.
13. Lee, D. H., H. S. Jeong, T. E. Kim, S. H. Oh, J. Lee, and I. S. Kim. 2008. Real-time RT-PCR for validation of reovirus type 3 safety during the manufacture of mammalian cell culture-derived biopharmaceuticals. Kor. J. Microbiol. 44: 228-236.
14. Lovatt, A. 2002. Applications of quantitative PCR in the biosafety and genetic stability assessment of biotechnology products. Rev. Mol. Biotechnol. 82: 279-300.
15. Martins, S. A. M., D. M. F. Prazeres, J. M. S. Cabral, and G. A. Monteiro. 2003. Comparison of real-time polymerase chain reaction and hybridization assays for the detection of Escherichia coli genomic DNA in process samples and pharmaceutical-grade plasmid DNA products. Anal. Biochem. 322: 127-129.
16. Monis, P. T. and S. Giglio. 2006. Nucleic acid amplification-based techniques for pathogen detection and identification. Infect. Genet. Evol. 6: 2-12.
17. Nissom, P. M. 2007. Specific detection of residual CHO host cell DNA by real-time PCR. Biologicals 35: 211-215.
18. Rathore, A. S., S. E. Sobacke, T. J. Kocot, D. R. Morgan, R. L. Dufield, and N. M. Mozier. 2003. Analysis for residual host cell proteins and DNA in process streams of a recombinant protein product expressed in Escherichia coli cells. J. Pharm. Biomed. Anal. 32: 1199-1211.
19. Rozen, S. and H. Skaletsky. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132: 365-386.
20. Swartz, J. R. 2001. Advances in Escherichia coli production of therapeutic proteins. Curr. Opin. Biotechnol. 12: 195-201.
21. Vilalta, A., V. Whitlow, and T. Martin. 2002. Real-time PCR determination of Escherichia coli genomic DNA contamination in plasmid preparations. Anal. Biochem. 301: 151-153.
22. Walsh, G. 2002. Proteins Biochemistry and Biotechnology, pp. 205-206. John Wiley & Sons Ltd, West Sussex, England.
23. Wang, K. U., Y. J. Guo, S. H. Sun, K. Shi, S. Zhang, K. H. Wang, Y. Zhang, and Z. H. Chen. 2006. 16S rRNA gene probe quantitates residual host cell DNA in pharmaceutical-grade plasmid DNA. Vaccine 24: 2656-2661.
24. Wit, C., C. Fautz, and Y. Xu. 2000. Real-time quantitative PCR for retrovirus-like particle quantification in CHO cell culture. Biologicals 28: 137-148.
25. Wolf, J. J., L. Wang, and E. Wang. 2007. Application of PCR technology in vaccine product development. Expert Rev. Vaccies 6: 547-558.
26. Wolter, T. and A. Richter. 2005. Assay for controlling host-cell impurities in biopharmaceuticals. BioProcess Int. 3: 40-46.
27. Workman, W. E. 1995. Sample preparation and residual DNA analysis of biopharmaceuticals. Pharmacopeia Forum 21: 479-483.